When are topical calcineurin inhibitors recommended for ashy dermatosis?

Ashy dermatosis, also called erythema dyschromicum perstans, causes grey-brown or slate-coloured patches that can persist or gradually extend. The diagnosis is clinical and may require careful comparison with other pigment conditions. A topical calcineurin inhibitor can calm immune activity in the skin without being a steroid. It may be chosen for sensitive areas or when a clinician wants an anti-inflammatory option suited to the treatment plan. It does not instantly remove established pigment, and improvement can be gradual.

Apply only the prescribed amount to the areas your clinician identified, using clean hands and avoiding the eyes and mucous membranes. A brief warm or stinging feeling can occur at first, but persistent burning, swelling, crusting, or worsening irritation deserves medical advice. Protecting discoloured skin from ultraviolet exposure can reduce contrast and helps the clinician judge change over time. Do not add bleaching creams, exfoliants, or steroid products without discussing them, because irritation can make pigmentation harder to assess.

Seek review if new patches appear quickly, lesions become painful or ulcerated, or the pattern changes substantially. Contact your clinician if irritation does not settle, if infection-like oozing or crusting develops, or if there is no meaningful change during the agreed review period. A reassessment may be needed to confirm the diagnosis or revise the plan.

Ask what features support ashy dermatosis, which patches should receive treatment, and how progress will be judged when pigment changes slowly. Clarify sun protection, possible irritation, and the date for reassessment.